HURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TuHURA Biosciences Inc (HURA) is not a strong buy for a beginner, long-term investor at this moment. Despite a positive MACD and analyst optimism, the company's financial performance is weak, with significant losses and no revenue growth. Additionally, there are no recent news catalysts, trading trends, or proprietary trading signals to support an immediate buy decision.
The MACD histogram is positive at 0.0738 and expanding, indicating bullish momentum. However, RSI is at 78.286, in the neutral zone, and moving averages are converging, suggesting no clear trend. The stock is trading near resistance levels (R1: 1.67), which could limit immediate upside potential.
Analyst Robert Burns from H.C. Wainwright maintains a Buy rating with a revised price target of $10, citing upcoming value inflection points and the recent stock decline as an attractive entry point.
The company's financials are weak, with no revenue growth, a net income loss of -7.1M in Q3 2025, and a significant drop in EPS (-99.71% YoY). There are no significant hedge fund or insider trading trends, and no recent news or congress trading data to act as catalysts.
In Q3 2025, revenue remained at $0 (0% YoY growth), net income improved to -7,104,544 (up 252.93% YoY), and EPS dropped to -0.14 (-99.71% YoY). Gross margin remained at 0%. Overall, the financials reflect poor performance with no revenue growth and continued losses.
H.C. Wainwright analyst Robert Burns lowered the price target from $12 to $10 but maintained a Buy rating, citing the stock's decline as an attractive entry point and highlighting potential value inflection points.
